Trogarzo

(Ibalizumab-uiyk)

Trogarzo

Drug updated on 1/4/2024

Dosage FormInjectable (intravenous: 150 mg/mL)
Drug ClassCD4-directed post-attachment HIV-1 inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • In combination with other antiretroviral(s), Trogarzo is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Product Monograph / Prescribing Information

Document TitleYearSource
Trogarzo (ibalizumab-uiyk) Prescribing Information.2022Theratechnologies Inc., Montréal, Québec, Canada

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Phase 3 study of ibalizumab for multidrug-resistant HIV-1.
40Subjects
F: 15%
M: 85%
2018N Engl J Med

Sex Distribution:

F:15%
M:85%
40Subjects

Year:

2018

Source:N Engl J Med

Clinical Practice Guidelines